BofA lowered the firm’s price target on Myriad Genetics (MYGN) to $9 from $11 and keeps an Underperform rating on the shares.

Fintel reports that on April 9, 2025, Guggenheim downgraded their outlook for Myriad Genetics (NasdaqGS:MYGN) from Buy to ...

SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics ...

Myriad Genetics, Inc.’s MYGN Oncology growth strategy, which focuses on expanding companion diagnostics and market growth through new clinical guidelines, is poised to drive growth in the upcoming ...

Myriad Genetics (MYGN) announced the appointment of Brian Donnelly as CCO, effective May 1, 2025. Prior to joining Myriad Genetics, Donnelly ...

Shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) have earned a consensus rating of “Hold” from the fifteen research firms that are currently covering the firm, Marketbeat reports. Three ...

Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its target price lowered by Scotiabank from $24.00 to $20.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has a ...

In the preceding three months, 10 analysts have released ratings for Myriad Genetics MYGN, presenting a wide array of perspectives from bullish to bearish. Summarizing their recent assessments ...

SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today that in connection with ...